Clinical Trial

A First-in-Human Single and Multiple Ascending Dose Study of MT-701

Completed Phase 1
View on ClinicalTrials.gov →
Summary
First-in-human study to evaluate the safety, tolerability, pharmacokinetics (PK), and immunogenicity of single and multiple doses of MT-701 in healthy participants.
Protocol Amendment History 4 changes
critical Trial completed 2026-05-27
notable Enrollment reduced: 78 -> 46 participants 2026-05-27
notable Primary completion moved earlier: 2026-10-01 -> 2026-04-16 2026-05-27
minor Completion moved earlier: 2026-10-01 -> 2026-04-16 2026-05-27
Trial Details
NCT Number NCT07396909
Lead Sponsor Mirador Therapeutics, Inc.
Conditions Healthy Volunteers
Enrollment 46 participants
Start Date 2026-01-12
Primary Completion 2026-04-16 (estimated)
Study Completion 2026-04-16 (estimated)
Updated on ClinicalTrials.gov 2026-05-26